Retatrutide vs Mounjaro: Triple Agonist vs Dual Agonist for Diabetes

Overview

Retatrutide and Mounjaro (tirzepatide) are both Eli Lilly molecules for type 2 diabetes: one still in trials, one approved. Mounjaro is tirzepatide’s brand name for type 2 diabetes (the same molecule is sold as Zepbound for obesity). It won FDA approval in 2022 and has become a highly effective treatment for blood sugar control and weight in adults with type 2 diabetes.

Here we look only at diabetes, where the outcomes that matter most are HbA1c reduction, protecting beta-cell function and metabolic gains beyond glucose. Retatrutide adds glucagon receptor activation, and since glucagon is well known to raise blood sugar, that raises specific questions in diabetes.

Important note: No head-to-head trial has compared retatrutide with Mounjaro in type 2 diabetes. Cross-trial comparisons have major methodological limits and should be read with caution.

Why This Comparison Matters

Retatrutide versus Mounjaro is one of the most important comparisons in metabolic medicine right now:

• The same company (Eli Lilly) makes both, so the comparison isolates one question: does adding a third receptor (glucagon) to an already effective dual agonist bring a clinically meaningful benefit?
• Both target type 2 diabetes, where goals go beyond weight loss to blood sugar control, lowering cardiovascular risk and managing related conditions such as MASLD
• It has direct practical stakes: people on Mounjaro will want to know whether retatrutide offers enough extra benefit to switch once it is available
• With TRIUMPH-4 Phase 3 data out, the comparison is no longer theoretical. Retatrutide has Phase 3-level evidence for its weight loss

Understanding Mounjaro and Zepbound

One point matters for patients and clinicians alike: Mounjaro and Zepbound contain the same active molecule (tirzepatide) at the same doses. The difference is purely regulatory and commercial:

• Mounjaro is approved for type 2 diabetes (doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg)
• Zepbound is approved for chronic weight management in obesity (doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg)

Because this page is about diabetes, we refer to Mounjaro. The pharmacology is identical whatever the brand name.

Mechanism of Action in Diabetes

Mounjaro (Tirzepatide)

Tirzepatide’s dual GIP/GLP-1 action improves blood sugar in several ways:

• GLP-1 receptor activation boosts glucose-dependent insulin release from pancreatic beta cells, curbs unneeded glucagon release from alpha cells and slows gastric emptying (blunting blood sugar spikes after meals)
• GIP receptor activation adds more insulin release, especially after meals, and may help preserve beta cells through growth-supporting effects
• The large weight loss tirzepatide produces reduces insulin resistance, improving blood sugar further through an indirect but clinically important route

In the SURPASS Phase 3 program, Mounjaro lowered HbA1c by 2.0 to 2.4% from baseline, and up to 97% of patients reached HbA1c <7% at the highest dose.

Retatrutide

Retatrutide adds glucagon receptor activation to the GIP/GLP-1 backbone. In diabetes this looks like a paradox: glucagon normally raises blood sugar by making the liver release glucose, yet retatrutide controls blood sugar strongly. Several factors explain it:

• Insulin released through GLP-1 and GIP offsets glucagon-driven glucose release from the liver
• When insulin signaling is adequate, glucagon receptor activation favors fat burning over breaking down stored glycogen
• Weight loss and less liver fat from glucagon receptor activation improve the underlying insulin sensitivity
• Overall, blood sugar balance is kept or improved despite glucagon receptor activity

In Phase 2 in type 2 diabetes, retatrutide 12 mg lowered HbA1c by about 2.02%, confirming that the glucagon component does not undermine glucose control.

TRIUMPH-4 Phase 3 Update

In December 2025, Eli Lilly announced results from TRIUMPH-4, the first Phase 3 trial in the retatrutide program. TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis, not type 2 diabetes, but its weight loss data are highly relevant to diabetes care:

• Retatrutide 12 mg achieved -28.7% mean weight loss at 68 weeks, the largest ever reported for any drug in a Phase 3 trial
• Retatrutide 9 mg achieved -26.4% mean weight loss at the same timepoint
• 58.6% of participants at 12 mg lost at least 25% of their body weight, versus 1.3% on placebo

These results beat the Phase 2 data (-24.2% at 48 weeks) and far exceed the weight loss seen with Mounjaro in its SURPASS trials. For people with diabetes, weight loss on this scale has major implications for insulin resistance, metabolic health and possible remission.

The parallel TRANSCEND program tests retatrutide specifically in type 2 diabetes. TRANSCEND-T2D-1 reported positive topline results on March 19, 2026 (Eli Lilly press release): HbA1c reductions of 1.7-2.0 percentage points and weight loss of 11.1-16.6 kg across doses, with blood sugar control comparable to tirzepatide and more weight loss. The full results, published in The Lancet on June 6, 2026, showed an HbA1c reduction of 1.94 points and weight loss of 15.3% at 12 mg over 40 weeks. The pivotal obesity trial TRIUMPH-1 also reported on May 21, 2026: -28.3% at 12 mg/80 weeks in 2,339 adults without diabetes. TRIUMPH-2 (obesity with type 2 diabetes) reported on July 23, 2026 (-20.8% weight loss and A1C -1.5 points at 12 mg over 80 weeks), and on October 28, 2026 Lilly announced topline results from TRANSCEND-T2D-2, a head-to-head trial against semaglutide 2 mg (A1C -2.2 points on retatrutide 9 mg and 12 mg vs -1.8 on semaglutide; not yet peer reviewed).

Efficacy Comparison

Glycemic Control

On the data so far, the two drugs lower blood sugar by broadly similar amounts. Mounjaro has the advantage of extensive Phase 3 testing across many trials (SURPASS-1 through SURPASS-5). Retatrutide now has Phase 3 diabetes data from TRANSCEND-T2D-1 (published June 2026) and TRIUMPH-2, plus topline results from TRANSCEND-T2D-2 against semaglutide.

Weight Loss in Diabetes

People with diabetes usually lose less weight than people with obesity alone, because of insulin resistance and other metabolic factors:

TRIUMPH-2 enrolled adults with obesity and type 2 diabetes. In TRIUMPH-4 (obesity with knee OA), retatrutide 12 mg produced -28.7% at 68 weeks.

Retatrutide produced numerically more weight loss in people with diabetes. That may matter clinically, since weight loss is a key part of managing diabetes and lowering cardiovascular risk. The extra energy use from glucagon receptor activation may be especially useful in diabetes, where insulin resistance can hold weight loss back.

Liver Fat and MASLD

Non-alcoholic fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease, or MASLD) is very common in type 2 diabetes, affecting an estimated 55 to 70% of patients. This is where retatrutide’s glucagon receptor activation may offer its most meaningful advantage:

• Mounjaro lowers liver fat mainly through weight loss and better insulin sensitivity, with moderate reductions
• Retatrutide stimulates fat burning in the liver directly through the glucagon receptor, cutting liver fat by about 82% in relative terms in Phase 2

For people with both type 2 diabetes and significant fatty liver, this difference could matter. Eli Lilly’s SYNERGY trial is testing retatrutide specifically for MASH, with liver biopsy endpoints.

Safety in the Diabetes Context

Hypoglycemia Risk

Neither tirzepatide nor retatrutide carries much built-in risk of low blood sugar, because the insulin release they trigger depends on glucose. In theory, retatrutide’s glucagon component adds a further buffer against hypoglycemia by keeping up glucose release from the liver. Phase 2 confirmed low hypoglycemia rates with retatrutide, similar to tirzepatide.

Gastrointestinal Tolerability

GI side effects tend to be somewhat less common in people with diabetes than in people with obesity alone:

Phase 3 TRIUMPH-4 data show far higher GI rates with retatrutide than with Mounjaro (nausea 43.2% vs 18%, diarrhea 33.1% vs 17%, vomiting 20.9% vs 9%). That suggests the glucagon component, the drug’s greater overall potency, or both add to the GI burden. Note that the TRIUMPH-4 figures come from people with obesity over 68 weeks, while Mounjaro’s label figures come from people with diabetes, where GI rates tend to be lower. Both drugs use gradual dose increases to limit early GI side effects.

TRIUMPH-4 Safety Signal: Dysesthesia

TRIUMPH-4 found a new safety signal not seen in Phase 2: dysesthesia (abnormal sensations such as numbness, tingling or burning), reported in 20.9% of people on retatrutide 12 mg versus 0.7% on placebo. This sensory nerve disturbance is being closely evaluated in ongoing Phase 3 trials. Clinicians should keep it in mind while the full safety profile is worked out.

Cardiovascular Considerations

Cardiovascular risk is central to managing type 2 diabetes. Mounjaro’s cardiovascular outcomes trial, SURPASS-CVOT (more than 13,000 adults with type 2 diabetes and cardiovascular disease), reported in July 2025: tirzepatide met non-inferiority to dulaglutide for major adverse cardiovascular events, with an 8% lower risk (HR 0.92) that was not statistically superior. Retatrutide has no cardiovascular outcomes data in diabetes; TRIUMPH-Outcomes is running.

Current Status and Availability

Mounjaro

Mounjaro is FDA-approved, on the market and widely prescribed for type 2 diabetes. Its safety profile is established through the large SURPASS Phase 3 program and a growing body of real-world evidence.

Retatrutide

Retatrutide is still investigational as of October 31, 2026. It is in late-stage Phase 3 development through the TRIUMPH program (4 pivotal obesity trials plus TRIUMPH-Outcomes CVOT), the TRANSCEND program (type 2 diabetes) and the SYNERGY/MACELD programs (MASH). TRIUMPH-1 through TRIUMPH-4 and TRANSCEND-T2D-1 have all reported positive results, and TRANSCEND-T2D-2 reported topline results on October 28, 2026. No application has been filed. Lilly plans to file no later than Q1 2027, and the earliest possible FDA approval is estimated at late 2027 to early 2028. On October 2, 2026 the FDA ruled that retatrutide is a drug, not a biologic, so the application must be a New Drug Application (NDA); Lilly is contesting the FDA ruling in court. The only legitimate way to get retatrutide is by enrolling in an authorized clinical trial.

Key Differences Summary

Dosing and Administration

Both drugs are once-weekly injections under the skin from pre-filled pens, so using them feels much the same:

Both start low and step up every 4 weeks to limit GI side effects, and both need gradual titration to reach their top effective dose.

Who Might Benefit From Each

Mounjaro May Be Preferred For

• Patients who need an FDA-approved type 2 diabetes treatment they can start now
• Patients who want a well-understood safety profile backed by extensive Phase 3 data
• Patients whose main goal is blood sugar control (HbA1c reduction)
• Patients whose insurance covers Mounjaro for type 2 diabetes
• Patients happy with the weight loss they get from dual GIP/GLP-1 treatment

Retatrutide May Be Preferred For (Once Approved)

• Patients with type 2 diabetes plus significant MASLD/MASH who would benefit from glucagon’s effects on the liver
• Patients who need more weight loss than Mounjaro can deliver
• Patients who have not done well enough on dual GIP/GLP-1 treatment
• Patients in clinical trials who meet eligibility criteria

Clinical Implications

Mounjaro is currently the most effective approved drug for type 2 diabetes, with exceptional blood sugar control and clinically significant weight loss. Its Phase 3 evidence, FDA approval and growing real-world experience make it a well-understood choice for clinicians managing type 2 diabetes.

Retatrutide’s Phase 2 and Phase 3 diabetes data (TRANSCEND-T2D-1, TRIUMPH-2) suggest similar blood sugar control with more weight loss, and Phase 2 showed much larger liver fat reductions. The TRIUMPH-4 Phase 3 results confirmed that retatrutide produces more weight loss than any approved drug.

For diabetes, the key question is whether adding glucagon receptor activation brings real clinical benefit beyond what dual GIP/GLP-1 treatment already does. No trial has compared retatrutide with tirzepatide in type 2 diabetes, and retatrutide is not approved. Mounjaro remains the evidence-based choice for clinicians who want the most effective approved incretin drug for type 2 diabetes.

Frequently Asked Questions

Is retatrutide better than Mounjaro for diabetes?

Across trials, retatrutide and Mounjaro control blood sugar about equally well (HbA1c reductions of about 2 points; -1.94 at 12 mg in the Phase 3 TRANSCEND-T2D-1 trial). Retatrutide produced more weight loss and, in Phase 2, much larger liver fat reductions. No trial has compared the two directly in type 2 diabetes. Mounjaro has a well-established evidence base from the SURPASS program and is FDA-approved; retatrutide is not.

Can I switch from Mounjaro to retatrutide?

No. Retatrutide is not approved and is only available in clinical trials. If you take Mounjaro, do not stop it in anticipation of retatrutide. The earliest possible approval for retatrutide is late 2027 to mid-2028 (Lilly plans to file no later than Q1 2027).

Does retatrutide cause blood sugar to rise because of the glucagon component?

No. Glucagon does raise blood sugar, but retatrutide does not worsen glucose control. Insulin released through the GLP-1 and GIP receptors offsets glucagon-driven glucose release from the liver. In Phase 2 in type 2 diabetes, retatrutide 12 mg lowered HbA1c by about 2.02%.

What is the TRIUMPH-4 trial and why does it matter for diabetes patients?

TRIUMPH-4 was the first Phase 3 retatrutide trial to report results (December 2025). It enrolled adults with obesity and knee osteoarthritis and showed -28.7% weight loss at 12 mg over 68 weeks. It was not a diabetes trial, but weight loss on that scale matters a great deal for insulin resistance and metabolic health. The separate TRANSCEND program tests retatrutide specifically in type 2 diabetes; TRANSCEND-T2D-1 was published in The Lancet in June 2026.

What is the difference between two receptors and three receptors?

Mounjaro activates two receptors (GIP and GLP-1), which mainly boost insulin release and curb appetite. Retatrutide activates the same two plus the glucagon receptor. That third receptor raises energy use through heat production and fat burning in the liver, and clears liver fat directly. It is why retatrutide produces more weight loss and much larger liver fat reductions than Mounjaro.

Will Eli Lilly replace Mounjaro with retatrutide?

Unlikely. Eli Lilly presents them as complementary products. Mounjaro (dual agonist) is expected to stay the established diabetes treatment, while retatrutide (triple agonist) may serve patients who need more weight loss or who have conditions like MASLD where glucagon receptor activation adds benefit. The two meet different clinical needs.

What is the cost likely to be for retatrutide compared to Mounjaro?

Retatrutide has no announced price because it is not yet approved. Mounjaro’s US list price has been above $1,000 per month since at least November 2023 (about $1,023 then), though insurance and discount programs can lower what you pay. Since retatrutide is a more complex triple agonist from the same company, its price is expected to be similar or possibly higher. The actual price will depend on the market, insurance negotiations and Eli Lilly’s strategy at launch.